Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist

Core Viewpoint - Idorsia Ltd has initiated a Phase 2 proof-of-concept trial for IDOR-1117-2520, an oral selective CCR6 receptor antagonist aimed at treating moderate-to-severe psoriasis, with potential implications for other autoimmune conditions associated with CCR6 and Th17 pathways [2][10]. Company Overview - Idorsia is focused on developing transformative medicines and aims to evolve into a leading biopharmaceutical company with a strong scientific foundation [13]. - The company is headquartered near Basel, Switzerland, and has a dedicated team covering all aspects of drug development [14]. Product Details - IDOR-1117-2520 is a first-in-class, oral small-molecule drug designed to block the CCL20-driven recruitment of pathogenic CCR6-expressing immune cells, showing efficacy comparable to existing IL-17 and IL-23 inhibitors in preclinical models [9]. - The drug is currently in a Phase 2 trial, with results expected in the first quarter of 2027 [6]. Clinical Trial Information - The Phase 2 trial is a multicenter, double-blind, randomized, placebo-controlled study involving approximately 30 participants, evaluating the efficacy and safety of two dosages of IDOR-1117-2520 over 12 weeks [6]. - Primary efficacy will be measured by the change in Psoriasis Area and Severity Index (PASI) score from baseline to Week 12 [6]. Mechanism of Action - The CCR6 antagonism targets a key receptor that directs pathogenic immune cells to inflamed tissues, potentially modulating inflammation without broad immunosuppression [8]. - The Th17 pathway, which is implicated in various autoimmune diseases, is a primary focus for IDOR-1117-2520, aligning with Idorsia's strategic goals [4][11].